Comparing pharmacophore models derived from crystallography and NMR ensembles

NMR and X-ray crystallography are the two most widely used methods for determining protein structures. Our previous study examining NMR versus X-Ray sources of protein conformations showed improved performance with NMR structures when used in our Multiple Protein Structures (MPS) method for receptor-based pharmacophores (Damm, Carlson, J Am Chem Soc 129:8225–8235, 2007). However, that work was based on a single test case, HIV-1 protease, because of the rich data available for that system. New data for more systems are available now, which calls for further examination of the effect of different sources of protein conformations. The MPS technique was applied to Growth factor receptor bound protein 2 (Grb2), Src SH2 homology domain (Src-SH2), FK506-binding protein 1A (FKBP12), and Peroxisome proliferator-activated receptor-γ (PPAR-γ). Pharmacophore models from both crystal and NMR ensembles were able to discriminate between high-affinity, low-affinity, and decoy molecules. As we found in our original study, NMR models showed optimal performance when all elements were used. The crystal models had more pharmacophore elements compared to their NMR counterparts. The crystal-based models exhibited optimum performance only when pharmacophore elements were dropped. This supports our assertion that the higher flexibility in NMR ensembles helps focus the models on the most essential interactions with the protein. Our studies suggest that the “extra” pharmacophore elements seen at the periphery in X-ray models arise as a result of decreased protein flexibility and make very little contribution to model performance.

[1]  J. M. Bradshaw,et al.  Probing the "two-pronged plug two-holed socket" model for the mechanism of binding of the Src SH2 domain to phosphotyrosyl peptides: a thermodynamic study. , 1998, Biochemistry.

[2]  J. Andrew McCammon,et al.  Method for Including the Dynamic Fluctuations of a Protein in Computer-Aided Drug Design , 1999 .

[3]  Heather A Carlson,et al.  Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.

[4]  Cheng Peng,et al.  Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking , 2012, International journal of molecular sciences.

[5]  Yu-Quan Wei,et al.  Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. , 2008, Journal of molecular graphics & modelling.

[6]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[7]  U. Deva Priyakumar,et al.  Dynamics Based Pharmacophore Models for Screening Potential Inhibitors of Mycobacterial Cyclopropane Synthase , 2015, J. Chem. Inf. Model..

[8]  Alexander D. MacKerell,et al.  Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling , 2014, J. Comput. Aided Mol. Des..

[9]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[10]  David Ryan Koes,et al.  Pharmacophore Modeling: Methods and Applications , 2015 .

[11]  Gerhard Wolber,et al.  In Silico Prediction of Human Sulfotransferase 1E1 Activity Guided by Pharmacophores from Molecular Dynamics Simulations* , 2015, The Journal of Biological Chemistry.

[12]  F. Bushman,et al.  Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.

[13]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[14]  Anna L. Bowman,et al.  Approximating Protein Flexibility through Dynamic Pharmacophore Models: Application to Fatty Acid Amide Hydrolase (FAAH) , 2011, J. Chem. Inf. Model..

[15]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[16]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[17]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[18]  Heather A. Carlson,et al.  Automated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design , 2008, J. Comput. Aided Mol. Des..

[19]  D. Erdmann,et al.  Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.

[20]  D. Rognan,et al.  Protein-Ligand Pharmacophores: Concept, Design and Applications , 2015 .

[21]  S. Harrison,et al.  Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck , 1993, Nature.

[22]  Heather A Carlson,et al.  Gaussian-weighted RMSD superposition of proteins: a structural comparison for flexible proteins and predicted protein structures. , 2006, Biophysical journal.

[23]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[24]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[25]  Stefano Alcaro,et al.  A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins , 2015, J. Chem. Inf. Model..

[26]  Kam Y. J. Zhang,et al.  Pharmacophore modeling: advances, limitations, and current utility in drug discovery , 2014 .

[27]  Lei Fang,et al.  Pharmacophore Modeling using Site-Identification by Ligand Competitive Saturation (SILCS) Method with Multiple Probe Molecules , 2015 .

[28]  Tingjun Hou,et al.  Development and Evaluation of an Integrated Virtual Screening Strategy by Combining Molecular Docking and Pharmacophore Searching Based on Multiple Protein Structures , 2013, J. Chem. Inf. Model..

[29]  M. M. Sanders,et al.  From the protein's perspective: the benefits and challenges of protein structure-based pharmacophore modeling , 2012 .

[30]  Thierry Langer,et al.  Common Hits Approach: Combining Pharmacophore Modeling and Molecular Dynamics Simulations , 2017, J. Chem. Inf. Model..

[31]  Heather A Carlson,et al.  Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.

[32]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[33]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[34]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[35]  T. Dinis,et al.  Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach , 2017, PloS one.

[36]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[37]  Heather A. Carlson,et al.  Incorporating Dynamics in E. coli Dihydrofolate Reductase Enhances Structure-Based Drug Discovery , 2007, J. Chem. Inf. Model..

[38]  Alexander D. MacKerell,et al.  Pharmacophore Modeling Using Site-Identification by Ligand Competitive Saturation (SILCS) with Multiple Probe Molecules , 2015, J. Chem. Inf. Model..